Safety and cost-effectiveness of ponatinib versus other tyrosine kinase inhibitors as second-line therapy in patients with chronic myeloid leukemia in the United States

References

• NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Chronic myelogeneous leukemia. 2020. https://www.nccn.org/professionals/physician_gls/pdf/cml.pdf
   Google Scholar
• Reed SD, Anstrom KJ, Ludmer JA, et al. Cost-effectiveness of imatinib versus interferon-alpha plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia. Cancer. 2004;101(11):2574–2583.
   PubMed Web of Science ®Google Scholar
• Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–2405.
   PubMed Web of Science ®Google Scholar
• Apperley JF. Chronic myeloid leukaemia. Lancet. 2015;385(9976):1447–1459.
   PubMed Web of Science ®Google Scholar
• Smieliauskas F, Chien C-R, Shen C, et al. Cost-effectiveness analyses of targeted oral anti-cancer drugs: a systematic review. Pharmacoeconomics. 2014;32(7):651–680.
   PubMed Web of Science ®Google Scholar
• Miller GD, Bruno BJ, Lim CS. Resistant mutations in CML and Ph + ALL–role of ponatinib. Biol: Targets Ther. 2014;8:243–54.
   PubMedGoogle Scholar
• Iclusig (ponatinib) [prescribing information]. Ariad Pharmaceuticals Inc; December 2017.
   Google Scholar
• Cortes JE, Kim D-W, Pinilla-Ibarz J, et al. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med. 2013;369(19):1783–1796.
   PubMed Web of Science ®Google Scholar
• Kim T, Rea D, Schwarz M, et al. Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib. Leukemia. 2013;27(6):1316–1321.
   PubMed Web of Science ®Google Scholar
• Montani D, Bergot E, Günther S, et al. Pulmonary arterial hypertension in patients treated by dasatinib. Circulation. 2012;125(17):2128–2137.
   PubMed Web of Science ®Google Scholar
• McGarry LJ, Yang M, Chiroli S, et al. Indirect comparison of efficacy of PonatiniB versus bosutinib in 3rd-line chronic-phase chronic myeloid leukemia using iterative proportional fitting. Value Health. 2016;19(3):A137.
   Web of Science ®Google Scholar
• Shen C, Chien C-R, Geynisman DM, et al. A review of economic impact of targeted oral anticancer medications. Expert Rev Pharmacoecon Outcomes Res. 2014;14(1):45–69.
   PubMed Web of Science ®Google Scholar
• Cancer Stat Facts: Leukemia – Chronic Myeloid Leukemia (CML). National Cancer Institute [cited 2021 May 16]. Available from: https://seer.cancer.gov/statfacts/html/cmyl.html
   Google Scholar
• Baccarani M, Deininger MW, Rosti G, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia. Blood. 2013;122(6):872–884.
   PubMed Web of Science ®Google Scholar
• Weinstein MC, Siegel JE, Gold MR, et al. Recommendations of the panel on cost-effectiveness in health and medicine. JAMA. 1996;276(15):1253–1258.
   PubMed Web of Science ®Google Scholar
• Arias E, Xu J. United States Life Tables, 2015. Natl Vital Stat Rep. 2018 Nov;67(7):1–64. PMID: 30707669.
   Google Scholar
• Szabo SM, Levy AR, Davis C, et al. A multinational study of health state preference values associated with chronic myelogenous leukemia. Value Health. 2010;13(1):103–111.
   PubMed Web of Science ®Google Scholar
• United States Department of Labor. Bureau of Labor Statistics. Consumer price index [cited 2018 Dec 21].
   Google Scholar
• Ollendorf DA, Pearson SD. An integrated evidence rating to frame comparative effectiveness assessments for decision makers. Med Care. 2010;48(6):S145–S152.
   PubMed Web of Science ®Google Scholar
• Marseille E, Larson B, Kazi DS, et al. Thresholds for the cost-effectiveness of interventions: alternative approaches. Bull World Health Organ. 2015;93(2):118–124.
   PubMed Web of Science ®Google Scholar
• Ubel PA, Hirth RA, Chernew ME, et al. What is the price of life and why doesn’t it increase at the rate of inflation? Arch Intern Med. 2003;163(14):1637–1641.
   PubMed Web of Science ®Google Scholar
• Timmers L, Beckeringh JJ, van Herk‐Sukel MP, et al. Use and costs of oral anticancer agents in The Netherlands in the period 2000–2008. Pharmacoepidemiol Drug Saf. 2012;21(10):1036–1044.
   PubMed Web of Science ®Google Scholar
• Marchetti M. Cost-effectiveness of kinase inhibitors for hematologic malignancies: a systematic and critical review. Expert Rev Pharmacoecon Outcomes Res. 2017;17(5):469–480.
   PubMed Web of Science ®Google Scholar
• Jabbour EJ, Lin J, Siegartel LR, et al. Evaluation of healthcare resource utilization and incremental economic burden of patients with chronic myeloid leukemia after disease progression to blast phase. J Med Econ. 2017;20(9):1007–1012.
   PubMed Web of Science ®Google Scholar
• Iannazzo S, McGarry L, Chiroli S. Cost-effectiveness analysis of ponatinib in the treatment of chronic-phase chronic myeloid leukemia (CP-CML) in Sweden. Value Health. 2015;18(7):A668.
   PubMed Web of Science ®Google Scholar
• Whalen J, Stillman I, Ambavane A, et al. Cost-effectiveness analysis of second-line tyrosine kinase inhibitor treatment for chronic myelogenous leukemia. J Med Econ. 2016;19(5):445–461.
   PubMed Web of Science ®Google Scholar
• Lucioni C, Iannazzo S, Mazzi S, et al. Cost-effectiveness of ponatinib in chronic myeloid leukemia in Italy. Global Regional Health Technol Assess. 2015;2(1):GRHTA.5000189.
   Web of Science ®Google Scholar
• Aichberger KJ, Herndlhofer S, Schernthaner GH, et al. Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML. Am J Hematol. 2011;86(7):533–539.
   PubMed Web of Science ®Google Scholar
• Fullmer A, Kantarjian H, Cortes J, et al. Dasatinib for the treatment of chronic myeloid leukemia. Expert Rev Hematol. 2011;4(3):253–260.
   PubMed Web of Science ®Google Scholar
• De Lavallade H, Punnialingam S, Milojkovic D, et al. Pleural effusions in patients with chronic myeloid leukaemia treated with dasatinib may have an immune-mediated pathogenesis. Br J Haematol. 2008;141(5):745–747.
   PubMed Web of Science ®Google Scholar
• Quintás-Cardama, A., Cortés, J. E., & Kantarjian, H. (2008). Practical management of toxicities associated with tyrosine kinase inhibitors in chronic myeloid leukemia. Clinical Lymphoma and Myeloma, 8, S82–S88.
   PubMedGoogle Scholar
• Rochau U, Sroczynski G, Wolf D, et al. Cost-effectiveness of the sequential application of tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia. Leuk Lymphoma. 2015;56(8):2315–2325.
   PubMed Web of Science ®Google Scholar